NAD+/Carnitine Amino Blend

NAD+ / L-Carnitine blend

NAD+/Carnitine Amino Blend (NAD+ / L-Carnitine blend) is a blends & other research compound. Combines NAD+ (mitochondrial energy/repair) with carnitine (fatty-acid transport) for an energy + fat-metabolism stack.

How NAD+/Carnitine Amino Blend works

Combines NAD+ (mitochondrial energy/repair) with carnitine (fatty-acid transport) for an energy + fat-metabolism stack.

Proposed benefits

A combination formula — proposed benefits reflect the sum of its individual components.

Where to get NAD+/Carnitine Amino Blend

The evidence for NAD+/Carnitine Amino Blend

Graded by what exists behind each claim.

✅ Clinically validated

• No trial of the blend. Its components have separate human literature — NAD+ precursors have small trials, and L-carnitine has a substantial one, including work showing benefit only where carnitine status is genuinely low.

📊 Correlative data

• Used for energy and metabolic support. As with every blend, the reported effect is hard to attribute to any one component.

🧪 Theoretical / extrapolated

• Two arms of the same pathway: NAD+ is the cofactor mitochondria need to oxidize fuel, and carnitine is the shuttle that carries long-chain fatty acids into them.
• Combining them is mechanistically coherent — supplying fuel transport without the cofactor to burn it, or the reverse, is the argument for a blend. The honest caveat is that neither is usually the limiting factor in someone healthy and well fed.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What NAD+/Carnitine Amino Blend actually does

Begin with the number on this site's own card, because it is not a dose. The card says 50–100 units (reconstituted). A ‘unit’ on an insulin syringe is a volume: 100 units is 1 milliliter. So the stated dose is 0.5 to 1.0 mL of a liquid whose concentration is nowhere specified — not on this card, not by the compounding pharmacies that make it, not by the vendors that sell it. Two vials with identical labels can differ severalfold in every ingredient. That is a structural fact about compounded blends and it has to come before any mechanism, because without milligrams per milliliter no mechanism can be dosed.

What is in it, per this site's own data: NAD+, L-carnitine, and amino acids. The site's dosing record states it plainly — NAD+ with L-carnitine and amino acids, with no trial of the combination — and the amino acid fraction is never identified, by anyone. Which amino acids, at what ratio, for what reason: unstated. So this page can attribute claims to two of the three components and has to say so about the third.

NAD+ itself, and the chemistry decides the argument. Nicotinamide adenine dinucleotide is 663.4 Da and carries two phosphate groups in a pyrophosphate bridge. At blood pH those are ionized, so NAD+ is a di-anion, and a charged 663 Da molecule does not diffuse across a lipid bilayer. Cells do not take up intact NAD+. What they take up are its fragments: extracellular NAD+ is attacked by cell-surface ectoenzymes — the NAD glycohydrolase CD38, and the nucleotide pyrophosphatases and 5′-nucleotidase CD73 — which cleave it down to nicotinamide mononucleotide, then to nicotinamide riboside and nicotinamide. Those are neutral, small, and carried into cells on nucleoside transporters, where the salvage pathway rebuilds NAD+ inside.

That is the honest version of the ‘NAD+ injection’ idea, and it is not the version being sold. Injecting NAD+ does not put NAD+ in a cell. It puts a slowly hydrolyzing depot of NAD+ precursors into the extracellular space, which the cell then takes up as nicotinamide riboside and nicotinamide — the same molecules an oral precursor supplies. The route bypasses first-pass hepatic extraction, which is a real advantage and is the site's own stated argument for it. What it does not do is deliver a different molecule to a different place.

Carnitine, and the mechanism is precise enough to say when it cannot work. Long-chain fatty acids cannot cross the inner mitochondrial membrane as acyl-CoA. Carnitine palmitoyltransferase-1 on the outer membrane transfers the acyl group from CoA to carnitine; the carnitine-acylcarnitine translocase carries the acylcarnitine in; CPT2 hands it back to CoA on the inside. Carnitine is the obligatory shuttle, and the claim “it transports fat into the mitochondria” is literally true.

And here is why that does not make supplementation work in a healthy person. The rate-limiting step of that shuttle is not carnitine availability — it is inhibition of CPT1 by malonyl-CoA, the product of acetyl-CoA carboxylase and the cell's signal that it is in a fed, lipogenic state. In someone with normal carnitine status the carrier is present in excess and the gate is held shut from the other side. Adding carrier to a system whose bottleneck is a closed gate changes nothing. That is exactly why the carnitine literature that works is in deficiency — hemodialysis, primary carnitine transporter defects, organic acidurias — and why Alhasaniah 2023 frames the whole field that way and closes by saying such findings “must be viewed with caution”.

Cell, rodent, human — and where it stops

There is no trial of this blend. There has never been one. So the chain has to be walked separately for each component, and the important discovery is that neither component's evidence used the molecule or the route in this vial.

The NAD arm, trial one. Martens 2018 ran a 2 × 6-week randomized, double-blind, placebo-controlled crossover in healthy middle-aged and older adults and showed that chronic supplementation with nicotinamide riboside is well tolerated and effectively stimulates NAD+ metabolism. Its own framing of the physiological findings is careful — “initial insight”, with a suggestion that future trials should assess blood pressure and arterial stiffness. That is a real, well-designed human trial, and the intervention was an oral precursor.

The NAD arm, trial two. Brakedal 2022, the NADPARK study: 30 newly diagnosed, treatment-naive Parkinson's patients given 1,000 mg of nicotinamide riboside or placebo for 30 days. Cerebral NAD levels, measured by ³¹P magnetic resonance spectroscopy, rose significantly but variably; those whose brain NAD rose showed altered cerebral metabolism on FDG-PET and mild clinical improvement; transcription of mitochondrial, lysosomal and proteasomal processes was upregulated in blood cells and skeletal muscle; and inflammatory cytokines fell in serum and cerebrospinal fluid. Again: oral nicotinamide riboside, not injected NAD+.

The obstacle for the NAD arm, stated exactly. Neither randomized trial used the molecule in this vial, and neither used its route. There is no randomized controlled trial of injected NAD+ — intravenous or subcutaneous — against any endpoint. The mechanism section above argues the two converge, because extracellular NAD+ is degraded to the same precursors before anything enters a cell. That argument is chemistry, not a trial result, and it should be read as the reasoned extrapolation it is. The variability in Brakedal 2022 is the honest note to end on: even with a gram a day of a well-absorbed oral precursor, the rise in tissue NAD was significant but variable, and the clinical benefit tracked the people in whom it rose. The biomarker moves; the outcome follows it inconsistently.

The carnitine arm, and the trial is a withdrawal design, which makes it unusually informative. Sugiyama 2021 took 59 hemodialysis patients already receiving intravenous L-carnitine 1,000 mg per dialysis session, three times weekly, and randomized them to continue three times weekly, drop to once weekly, or switch to placebo, for six months. Reducing to once weekly significantly decreased plasma carnitine fractions and red-cell free carnitine (p < 0.001), decreasing further on placebo. Plasma B-type natriuretic peptide rose significantly in the placebo group (p = 0.03), and the change in the red-cell (C16 + C18:1)/C2 acylcarnitine ratio correlated positively with the change in BNP (β = 0.389, p = 0.005). And then the finding everyone skips: full withdrawal “did not influence cardiac function”. A biochemical marker moved, a wall-stress hormone moved, and the echocardiogram did not.

The obstacle for the carnitine arm is arithmetic. The dose in that trial was 1,000 mg intravenously per session, in patients whose carnitine is stripped out by dialysis three times a week. This blend delivers 0.5 to 1.0 mL subcutaneously, sharing that volume between NAD+, carnitine and unnamed amino acids, at a concentration nobody publishes. A subcutaneous bolus is practically limited to a milliliter or two before it becomes painful and poorly absorbed, which places a hard ceiling on the milligrams any component can contribute. The trial dose and the vial dose are not the same order of magnitude, and they are not aimed at the same population — the trial population was carnitine-depleted by a machine.

The amino acid arm. Nothing can be said, because nothing is disclosed. Amino acids in an injectable solution serve real purposes — glycine and arginine are common tonicity and stability excipients, and some carry pharmacology of their own — but with no identities and no amounts, this component has no literature to attach to it. Saying so is the only honest treatment.

NAD+/Carnitine Amino Blend pharmacokinetics — how much of it actually gets in

The card says ‘varies by component’, which is correct and can be made much more specific.

NAD+, in the extracellular space. An injected NAD+ molecule does not have a half-life in the usual sense; it has a conversion sequence. Cell-surface CD38 and CD73 cleave it stepwise to nicotinamide mononucleotide, nicotinamide riboside and nicotinamide, and it is those neutral fragments that cross membranes and enter the salvage pathway. The rate is therefore set by ectoenzyme density in the tissue the injection sits in, which is why an intravenous infusion and a subcutaneous depot are not interchangeable exposures even at the same milligram dose.

Then nicotinamide meets the enzyme that decides where it goes. The dominant clearance route for nicotinamide in humans is methylation by nicotinamide N-methyltransferase, which takes a methyl group from S-adenosylmethionine and produces methylnicotinamide plus S-adenosylhomocysteine. S-adenosylhomocysteine hydrolyzes to homocysteine. So a sustained nicotinamide load is a sustained draw on the methyl pool, and it generates homocysteine as a by-product. That is a specific, measurable, cheap consequence of this compound's disposal pathway, and it produces the one blood-test prediction on the page. (This site's 5-Amino-1MQ page runs the same enzyme in the opposite direction, and the two pages predict opposite movements of the same marker for coherent reasons.)

L-carnitine. Carnitine is a small zwitterion cleared by the kidney with active tubular reabsorption through the OCTN2 transporter, which is why plasma concentrations are defended tightly and why frank deficiency is usually a transporter or dialysis problem rather than a dietary one. Dietary bioavailability is route- and diet-dependent: Alhasaniah 2023 reports it is higher in vegetarians than in people who eat meat, because habitual intake downregulates absorption. Injection bypasses that entirely, which is the honest pharmacokinetic argument for putting carnitine in a syringe. What injection does not bypass is renal clearance: an injected load above the reabsorption capacity is excreted, and the Sugiyama 2021 withdrawal data shows how quickly the fractions fall once dosing is reduced.

The volume arithmetic, which bounds everything above. 100 units is 1 mL. Whatever the concentration, the total milligrams delivered by this card's dose is the concentration times one milliliter or less, split three ways. Against a carnitine trial dose of 1,000 mg per session Sugiyama 2021 and an oral NAD precursor trial dose of 1,000 mg per day Brakedal 2022, that is the calculation a reader should insist on doing — and the single question worth asking any vendor is milligrams per milliliter of each component. Without that number, none of the literature on this page can be connected to the vial.

What would have to be true, and how you would know it was not

Four predictions with a marker, a direction and a window. The first is a real clinical test almost nobody orders, and the second is the one that cuts against the compound.

1. The acylcarnitine profile should move only if you were actually low. Order free and total carnitine with a plasma acylcarnitine profile at baseline and at 8 weeks — this is a routine metabolic panel, widely available, and it is the only direct read-out this blend has. The mechanistic prediction is specific: a person with normal carnitine status should show little change, because OCTN2 reabsorption already defends the concentration and CPT1 is restrained by malonyl-CoA rather than by carrier supply. A person who is genuinely depleted should show a clear rise. Sugiyama 2021 also identifies the derived quantity worth watching — the red-cell (C16 + C18:1)/C2 ratio, whose change correlated with change in BNP at β = 0.389, p = 0.005.

2. The prediction that cuts against it: homocysteine should rise. Sustained nicotinamide exposure is disposed of by methylation, spending S-adenosylmethionine and generating S-adenosylhomocysteine, which hydrolyzes to homocysteine. Draw Homocysteine at baseline and at 12 weeks, holding B12, folate and B6 constant across the window because those move it far harder than this will. This is reasoned from the disposal pathway rather than measured on this blend, and it is the most falsifiable statement on the page: if homocysteine does not move on a sustained NAD+ load, the methyl-consumption argument is weaker than it looks.

3. TMAO should NOT rise — and this is the interesting one, because oral carnitine does raise it. Koeth 2013 showed that intestinal microbiota metabolize L-carnitine to trimethylamine, which the liver oxidizes to TMAO, and that this pathway promoted atherosclerosis; in the same work, plasma carnitine predicted cardiovascular risk across a cohort of 2,595 subjects. The whole pathway starts in the gut lumen. An injected dose never meets the microbiota. So the mechanistic prediction is that injected carnitine should raise TMAO far less than an equivalent oral dose — a genuinely testable claim that would, if true, be the strongest argument anyone has ever made for the injectable route. TMAO is a commercially available assay. Nobody has run it.

4. Nothing else on a standard panel should move, and the subjective effect deserves naming honestly. No liver enzyme, no lipid, no thyroid marker and no CBC parameter has a mechanistic reason to shift, and there is no validated blood test for tissue NAD+ status — Brakedal 2022 needed ³¹P magnetic resonance spectroscopy of the brain to measure it. The reliable sensation people report from an NAD+ injection is flushing, warmth and a pressure or nausea sensation that tracks how fast it goes in. That is a real, dose-rate-dependent pharmacological effect. It is not a measure of whether the compound worked.

What nobody has tested yet

Nobody has published what is in these vials. A single quantitative assay — NAD+, L-carnitine and total amino acids in milligrams per milliliter, across ten vials from five suppliers — would be the most useful piece of work anybody could do on this product. It requires standard analytical chemistry, no ethics approval and no volunteers, and until it exists every dose statement about this blend, including this site's own, is a statement about volume.

Nobody has measured whether injected NAD+ raises tissue NAD+ in a human. Brakedal 2022 did it for oral nicotinamide riboside with ³¹P magnetic resonance spectroscopy and found the rise significant but variable. The identical protocol with an injected NAD+ arm would settle the central claim of the entire injectable NAD industry, and it has never been run. The scanner time is the only expensive part.

Nobody has compared TMAO generation by route. The carnitine-to-TMAO pathway is microbial and luminal Koeth 2013; injection bypasses the lumen. A crossover study — oral carnitine one week, injected carnitine another, plasma TMAO at 24 hours — would produce a result with real clinical meaning for a supplement millions of people take by mouth, and it would either validate or demolish the main mechanistic argument for injecting it.

Nobody has tested the blend against its own components. The obvious four-arm study — blend, NAD+ alone, carnitine alone, saline — with the acylcarnitine profile, homocysteine and a fixed submaximal exercise test as endpoints, has never been attempted. Until it is, any effect attributed to the combination is attributed by assertion.

NAD+/Carnitine Amino Blend — its own safety story, not its class's

The first safety fact is that no safety statement is possible, and the reason is compositional rather than pharmacological. A safety profile requires knowing what is in the syringe and how much. For this product the identity of one component is undisclosed, and the concentration of all three is undisclosed. Everything below therefore attaches to a named component, and the honest limitation is that nobody can say how much of any of them a given injection delivers.

The carnitine risk that has a real cardiovascular literature behind it, and the reason it may not apply here. Koeth 2013 established that intestinal microbiota convert L-carnitine to trimethylamine, that the liver oxidizes this to TMAO, and that the pathway promoted atherosclerosis — with plasma carnitine predicting cardiovascular risk across 2,595 subjects. That is the single most serious published concern about carnitine supplementation. It is also a gut mechanism, and an injection does not pass through the gut. This page's position is that the risk is plausibly lower by this route and that nobody has measured it, which is why the TMAO draw is in the predictions section rather than being asserted either way.

The carnitine evidence base is a deficiency literature, and that cuts both ways. Alhasaniah 2023 is explicit that carnitine's clear value is in primary carnitine deficiency and some secondary deficiencies such as organic acidurias, where it relieves hypotonia, muscle weakness and wasting, and that the wider claims “must be viewed with caution”. Sugiyama 2021, in a population depleted by dialysis, found withdrawal moved BNP but did not influence cardiac function. A replete person is not the population any of that describes, and the corresponding risk is not toxicity but irrelevance.

The NAD arm's real-world adverse effect is rate-dependent and belongs to the route. Flushing, warmth, chest pressure and nausea during administration are the consistent report from injectable NAD+, they scale with how fast the dose goes in, and they are the reason clinics infuse it slowly. That is a property of pushing a large bolus of a nucleotide into circulation, and a subcutaneous depot of 0.5–1 mL is a fundamentally gentler exposure than an intravenous infusion — a distinction worth making, because most safety advice written about ‘NAD+’ was written for a drip.

The oral precursor safety data, for what it transfers. Martens 2018 found chronic nicotinamide riboside well tolerated over a 2 × 6-week crossover in healthy older adults, and Brakedal 2022 found 1,000 mg daily for 30 days well tolerated in newly diagnosed Parkinson's patients. Those are reassuring and they are about an oral precursor over weeks, in populations that were being watched. There is no safety dataset of any kind for injected NAD+, for this blend, or for chronic use of either.

Sources read for this page

• Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.. Nat Commun 2018 · PMID 29599478
• Brakedal B, Dolle C, Riemer F, Ma Y, Nido GS, Skeie GO, Craven AR, Schwarzlmuller T, Brekke N, Diab J, Sverkeli L, Skjeie V, Varhaug K, Tysnes OB, Peng S, Haugarvoll K, Ziegler M, Gruner R, Eidelberg D, Tzoulis C. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.. Cell Metab 2022 · PMID 35235774
• Alhasaniah AH. l-carnitine: Nutrition, pathology, and health benefits.. Saudi J Biol Sci 2023 · PMID 36632072
• Sugiyama M, Hazama T, Nakano K, Urae K, Moriyama T, Ariyoshi T, Kurokawa Y, Kodama G, Wada Y, Yano J, Otsubo Y, Iwatani R, Kinoshita Y, Kaida Y, Nasu M, Shibata R, Tashiro K, Fukami K. Effects of Reducing L-Carnitine Supplementation on Carnitine Kinetics and Cardiac Function in Hemodialysis Patients: A Multicenter, Single-Blind, Placebo-Controlled, Randomized Clinical Trial.. Nutrients 2021 · PMID 34073024
• Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.. Nat Med 2013 · PMID 23563705

NAD+/Carnitine Amino Blend — safety, predicted from mechanism

NAD+/Carnitine Amino Blend — interference & stacking

Bloodwork to run alongside NAD+/Carnitine Amino Blend

Baseline first, then again at 8–12 weeks.

The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.

Check results you already have → · All 103 markers A–Z

NAD+/Carnitine Amino Blend — frequently asked questions

What NAD+/Carnitine Amino Blend is used for

NAD+/Carnitine Amino Blend appears under 1 goal in the goal router.

Related Blends & Other compounds

← Explore the full Protocol Vault

↑ Back to on this page